目的：评价中药对重症肌无力疗后复发及重症肌无力危象发生率的影响效果。方法：检索相关数据库，查找中药治疗重症肌无力的随机对照试验文献，对采集的数据进行系统评价。结果：共纳入13篇文献，包括1 137例患者。纳入文献质量均为低质量文献。研究显示：与西药组疗后复发率相比，中成药组有统计学意义（P < 0.000 01），“中成药+西药”组有统计学意义（P < 0.000 01），“中药复方+西药”组有统计学意义（P =0.000 03）；与西药组疗后肌无力危象发生率相比，“中成药+西药”组有统计学意义（P < 0.000 1），“中药复方+西药”组有统计学意义（P = 0.02）。结论：现有证据表明，中成药治疗重症肌无力后的复发率低；在西药基础上联用中成药或中药复方可以降低重症肌无力治疗后的复发率和肌无力危象发生率。但上述结论仍需大样本试验加以验证。

The aim of the study was to assess the effect of Chinese medicine in the treatment of myasthenia gravis on the incidence of recurrence and myasthenia gravis crisis. This study completely searched for Chinese medicine treatment ofmyasthenia gravis, which were randomized controlled trials from some Databases. The information was recorded andanalyzed. A total of 13 randomized controlled trials involving 1137 patients were included. All included literatures werelow-quality. Meta-analysis showed that, compared with the recurrence rate after treatment of myasthenia gravis in thewestern medicine group, there was statistical significance in the results of the Chinese patent medicine group (P <0.000 01), the western medicine plus Chinese patent medicine group (P < 0.000 01) and the western medicine plusChinese medicine compound group (P = 0.000 03). Compared with the incidence of myasthenia gravis crisis in thewestern medicine group, there was statistical significance in the results of the western medicine plus Chinese patentmedicine group (P < 0.00 01) and the western medicine plus Chinese medicine compound group (P = 0.02). The currentevidence confirmed that, the recurrence rate of Chinese patent medicine for myasthenia gravis was low; Chinese patentmedicine or Chinese medicine compound based on the use of western medicine can reduce the recurrence rate ofmyasthenia gravis and the incidence of myasthenia gravis crisis. However, the above conclusion still needs clinical trialswith large sample to be verified.

新疆维吾尔自治区自然科学基金（2014211C021）：新疆原发性干燥综合征气阴两虚证与miRNA-146a相关性研究，负责人：孙红艳；新疆医科大学科研创新基金（XYDCX201406）：原发性干燥综合征患者血miRNA-146a水平与气阴两虚证的相关性分析，负责人：孙红艳。